PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1926583-5 1991 Tacrine, a non-competitive inhibitor in concentrations below the inhibition constant (Ki = 1.4 x 10(-7) M) exerts the most intensive effect on the decarbamylation rate of methyl- and dimethylcarbamylated acetylcholinesterase of the mouse brain, while ambenonium and galanthamine in concentrations much (tens times) exceeding their Ki (3.1 x 10(-10) M and 4.4 x 10(-7) M, respectively) provide a decrease of the decarbamylation rate. Galantamine 266-278 acetylcholinesterase Mus musculus 204-224 8545521-11 1995 Acetylcholinesterase inhibitors heptylphysostigmine, galanthamine (0.63-2.5 mg/kg, IP) and tacrine (0.63-10.0 mg/kg, IP) all enhanced the rate of decrement of olfactory investigation when administered alone, but had differential effects on aggression. Galantamine 53-65 acetylcholinesterase Mus musculus 0-20 1954303-6 1991 Comparison with issues from mice revealed that galanthamine was selectively more potent in suppressing acetylcholinesterase in human erythrocytes. Galantamine 47-59 acetylcholinesterase Mus musculus 103-123 2274601-0 1990 Effects of different doses of galanthamine, a long-acting acetylcholinesterase inhibitor, on memory in mice. Galantamine 30-42 acetylcholinesterase Mus musculus 58-78 2626444-0 1989 Galanthamine, an acetylcholinesterase inhibitor: a time course of the effects on performance and neurochemical parameters in mice. Galantamine 0-12 acetylcholinesterase Mus musculus 17-37 34420968-0 2021 New Galantamine Derivatives with Inhibitory Effect on Acetylcholinesterase Activity. Galantamine 4-15 acetylcholinesterase Mus musculus 54-74 34420968-2 2021 One of the limited licensed AChE inhibitors (AChEIs) used as drugs is the natural compound galantamine (Gal). Galantamine 91-102 acetylcholinesterase Mus musculus 28-32 34420968-2 2021 One of the limited licensed AChE inhibitors (AChEIs) used as drugs is the natural compound galantamine (Gal). Galantamine 104-107 acetylcholinesterase Mus musculus 28-32 34420968-11 2021 CONCLUSION: The new galantamine-peptide hybrids demonstrated a potential for inhibition of AChE and antioxidant activity and deserve further attention. Galantamine 20-31 acetylcholinesterase Mus musculus 91-95 33806197-2 2021 A recently designed, synthesized and tested hybrid compound between the AChE inhibitor galantamine (GAL) and the antioxidant polyphenol curcumin (CU) showed high AChE inhibition in vitro. Galantamine 87-98 acetylcholinesterase Mus musculus 72-76 33806197-2 2021 A recently designed, synthesized and tested hybrid compound between the AChE inhibitor galantamine (GAL) and the antioxidant polyphenol curcumin (CU) showed high AChE inhibition in vitro. Galantamine 87-98 acetylcholinesterase Mus musculus 162-166 33806197-2 2021 A recently designed, synthesized and tested hybrid compound between the AChE inhibitor galantamine (GAL) and the antioxidant polyphenol curcumin (CU) showed high AChE inhibition in vitro. Galantamine 100-103 acetylcholinesterase Mus musculus 72-76 33806197-2 2021 A recently designed, synthesized and tested hybrid compound between the AChE inhibitor galantamine (GAL) and the antioxidant polyphenol curcumin (CU) showed high AChE inhibition in vitro. Galantamine 100-103 acetylcholinesterase Mus musculus 162-166 33806197-7 2021 In the ex vivo tests, the GAL-CU hybrid performed better than GAL and CU themselves; in a dose of 5 mg/kg, it demonstrates 25% reduction in AChE activity, as well as a 28% and 73% increase in the levels of MDA and GSH, respectively. Galantamine 26-29 acetylcholinesterase Mus musculus 140-144 2626444-1 1989 The time course of the effects of the long-acting acetylcholinesterase (AChE) inhibitor, galanthamine, on a spatial navigation task and on AChE and acetylcholine (ACh) levels were investigated in mice. Galantamine 89-101 acetylcholinesterase Mus musculus 50-70 2626444-1 1989 The time course of the effects of the long-acting acetylcholinesterase (AChE) inhibitor, galanthamine, on a spatial navigation task and on AChE and acetylcholine (ACh) levels were investigated in mice. Galantamine 89-101 acetylcholinesterase Mus musculus 72-76 2626444-7 1989 Galanthamine (5.0 mg/kg IP) significantly decreased cortical AChE activity and significantly increased cortical ACh content in control mice in a time-dependent manner. Galantamine 0-12 acetylcholinesterase Mus musculus 61-65 2626444-10 1989 AChE activity was inhibited by galanthamine in cortical homogenates with an IC50 of 4.1 x 10(-7) M.(ABSTRACT TRUNCATED AT 250 WORDS) Galantamine 31-43 acetylcholinesterase Mus musculus 0-4 3252244-1 1988 The effects of the long-acting acetylcholinesterase (AChE) inhibitor, galanthamine, on spatial memory were investigated in mice. Galantamine 70-82 acetylcholinesterase Mus musculus 53-57 953343-0 1976 [Galanthamine interaction with mouse brain acetylcholinesterase in in vivo experiments]. Galantamine 1-13 acetylcholinesterase Mus musculus 43-63 953343-1 1976 Armine treatment of mice against the background of preliminary galanthamine injection diminished the inhibition of the acetylcholinesterase of the brain caused by a reversible inhibitor. Galantamine 63-75 acetylcholinesterase Mus musculus 119-139 26322849-4 2015 Here, we show that galantamine, a centrally acting acetylcholinesterase inhibitor and an activator of the inflammatory reflex, attenuates murine experimental type 1 diabetes. Galantamine 19-30 acetylcholinesterase Mus musculus 51-71 27618041-6 2016 Calibration of AChE inhibitors, tacrine and galantamine, was performed, with limit of detection equal to 1.1 nM and 1.28 microM, respectively. Galantamine 44-55 acetylcholinesterase Mus musculus 15-19 26459156-0 2016 Induction of oral tremor in mice by the acetylcholinesterase inhibitor galantamine: Reversal with adenosine A2A antagonism. Galantamine 71-82 acetylcholinesterase Mus musculus 40-60 27150930-5 2016 Furthermore, we clarified the pharmacological profiles of the acetylcholinesterase inhibitors donepezil, galantamine, and rivastigmine, providing novel insights into their mechanisms of action. Galantamine 105-116 acetylcholinesterase Mus musculus 62-82 33022354-9 2021 Our results indicated that UA enantiomers evoked complex-receptor interaction with AChE like galantamine in silico. Galantamine 93-104 acetylcholinesterase Mus musculus 83-87 31302713-1 2019 PURPOSE: These studies determined whether the acetylcholinesterase inhibitors, donepezil and galantamine, both of which are approved for the treatment of cognitive deficits in Alzheimer"s disease, can prevent or reverse spatial memory deficits in mice induced by cyclophosphamide and doxorubicin, cytotoxic agents commonly used to treat breast cancer. Galantamine 93-104 acetylcholinesterase Mus musculus 46-66 28286520-6 2017 AChE inhibitors were measured with limits of detection, 149 nM and 22.3 nM for galanthamine and donepezil, respectively. Galantamine 79-91 acetylcholinesterase Mus musculus 0-4 17912499-2 2008 However, clinical data suggest that the acetylcholinesterase (AChE) inhibitors galantamine and donepezil have different effects on negative and cognitive symptoms in schizophrenia. Galantamine 79-90 acetylcholinesterase Mus musculus 40-60 24315193-2 2014 Thus, (11)C-labeled (-)-galanthamine and its enantiomers were synthesized as novel agents for imaging the localization and activity of AChE by positron emission tomography (PET). Galantamine 20-36 acetylcholinesterase Mus musculus 135-139 21820453-4 2011 In the present study, we investigated whether the acetylcholinesterase inhibitors donepezil and galantamine could influence neurotrophin receptor signaling in the brain. Galantamine 96-107 acetylcholinesterase Mus musculus 50-70 20958289-1 2011 BACKGROUND AND PURPOSE: We have previously reported that galantamine, a weak acetylcholinesterase inhibitor, improves prepulse inhibition (PPI) deficits in mice reared in social isolation. Galantamine 57-68 acetylcholinesterase Mus musculus 77-97 22355654-6 2011 Treatment of trisomic mice with the acetylcholinesterase inhibitor galantamine resulted in a significant improvement in olfactory learning. Galantamine 67-78 acetylcholinesterase Mus musculus 36-56 20219155-1 2010 Galantamine, a drug used to treat Alzheimer"s disease, inhibits acetylcholinesterase (AChE) and allosterically modulates nicotinic acetylcholine receptors (nAChRs) resulting in stimulation of catecholamine neurotransmission. Galantamine 0-11 acetylcholinesterase Mus musculus 64-84 20219155-1 2010 Galantamine, a drug used to treat Alzheimer"s disease, inhibits acetylcholinesterase (AChE) and allosterically modulates nicotinic acetylcholine receptors (nAChRs) resulting in stimulation of catecholamine neurotransmission. Galantamine 0-11 acetylcholinesterase Mus musculus 86-90 18639629-5 2009 Peripheral administration of the acetylcholinesterase inhibitor galantamine significantly reduced serum TNF levels through vagus nerve signaling, and protected against lethality during murine endotoxemia. Galantamine 64-75 acetylcholinesterase Mus musculus 33-53 18639629-6 2009 Administration of a centrally-acting muscarinic receptor antagonist abolished the suppression of TNF by galantamine, indicating that suppressing acetylcholinesterase activity, coupled with central muscarinic receptors, controls peripheral cytokine responses. Galantamine 104-115 acetylcholinesterase Mus musculus 145-165 17912499-2 2008 However, clinical data suggest that the acetylcholinesterase (AChE) inhibitors galantamine and donepezil have different effects on negative and cognitive symptoms in schizophrenia. Galantamine 79-90 acetylcholinesterase Mus musculus 62-66 16154210-12 2005 This retention deficit for cued fear conditioning is ameliorated by treatment with the AChE inhibitor galantamine. Galantamine 102-113 acetylcholinesterase Mus musculus 87-91 12522088-4 2003 Inhibition of both AChE and BChE with galanthamine (80 micro M), neostigmine (3-10 micro M), O-ethylS-2-(diisopropylamino)ethyl-methylphosphono-thioate (MTP) or phospholine decreased evoked transmitter release (20-50%). Galantamine 38-50 acetylcholinesterase Mus musculus 19-23